Evidence map›Paper›PMID 34503173›Full record

ArticleCancers2021

Genetic Alterations and Resectability Predict Outcome in Patients with Neuroblastoma Assigned to High-Risk Solely by

Frank Berthold, Angela Ernst, Sandra Ackermann, Christoph Bartenhagen, Holger Christiansen, Barbara Hero, Carolina Rosswog, Dietrich von Schweinitz, Thomas Klingebiel, Irene Schmid and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Frank BertholdDepartment of Pediatric Oncology and Hematology, University of Cologne, Kerpener Str. 62, 50924 Cologne, Germany.ORCID 0000-0002-7613-1723
Angela ErnstInstitute of Medical Statistics and Computational Biology, Medical Faculty, University of Cologne, 50924 Cologne, Germany.
Sandra AckermannCenter for Molecular Medicine Cologne (CMMC) and Department of Experimental Pediatric Oncology, Medical Faculty, University of Cologne, Kerpener Str. 62, 50924 Cologne, Germany.
Christoph BartenhagenCenter for Molecular Medicine Cologne (CMMC) and Department of Experimental Pediatric Oncology, Medical Faculty, University of Cologne, Kerpener Str. 62, 50924 Cologne, Germany.
Holger ChristiansenDepartment of Pediatric Oncology, Hematology and Hemostasiology, University of Leipzig, Liebigstr. 20a, 04103 Leipzig, Germany.
Barbara HeroDepartment of Pediatric Oncology and Hematology, University of Cologne, Kerpener Str. 62, 50924 Cologne, Germany.ORCID 0000-0003-4129-890X
Carolina RosswogCenter for Molecular Medicine Cologne (CMMC) and Department of Experimental Pediatric Oncology, Medical Faculty, University of Cologne, Kerpener Str. 62, 50924 Cologne, Germany.
Dietrich von SchweinitzDepartment of Pediatric Surgery, von Hauner Children's Hospital, Ludwig-Maximilians-University Munich, Lindwurmstr. 4, 80337 München, Germany.
Thomas KlingebielDepartment of Children and Adolescents, University Hospital, Goethe University Frankfurt, Theodor-Stern-Kai 7, 60596 Frankfurt, Germany.
Irene SchmidDepartment of Pediatric Surgery, von Hauner Children's Hospital, Ludwig-Maximilians-University Munich, Lindwurmstr. 4, 80337 München, Germany.
Thorsten SimonDepartment of Pediatric Oncology and Hematology, University of Cologne, Kerpener Str. 62, 50924 Cologne, Germany.ORCID 0000-0002-3425-8451
Matthias FischerCenter for Molecular Medicine Cologne (CMMC) and Department of Experimental Pediatric Oncology, Medical Faculty, University of Cologne, Kerpener Str. 62, 50924 Cologne, Germany.
University of Cologne · DELudwig-Maximilians-Universität München · DEGoethe University Frankfurt · DELeipzig University · DE

Funding

Deutsche Kinderkrebshilfe Grants 96.06 and 99.03Deutsche Krebshilfe Grant 70-2290-Be; Grant 70107712Else Kröner-Fresenius-Stiftung 2016-Kolleg-19
6 · The paper itself

Abstract

backgroundTo identify variables predicting outcome in neuroblastoma patients assigned to the high-risk group solely by the presence of

methodsClinical characteristics, genomic information, and outcome of 190 patients solely assigned to high-risk neuroblastoma by MNA were analyzed and compared to 205 patients with stage 4 neuroblastoma aged ≥18 months with MNA (control group).

resultsEvent-free survival (EFS) and overall survival (OS) at 10 years were 47% (95%-CI 39-54%) and 56% (95%-CI 49-63%), respectively, which was significantly better than EFS and OS of the control group (EFS 25%, 95%-CI 18-31%,

conclusionsNeuroblastoma patients attributed to high risk solely by

Indexed as

ALKhigh-risk neuroblastomaMYCN amplificationp53 pathwayRAS pathwayresectability

Identifiers

PMID34503173
PMCPMC8430929
OpenAlexW3198655428

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.